Subscribe
istock-909045842-peopleimages
peopleimages / iStockphoto.com
9 April 2019Americas

Alnylam and Regeneron unveil RNAi partnership

Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference (RNAi) therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Biotechnology
Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Biotechnology
Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Biotechnology
Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms
6 October 2020   Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
Europe
Regeneron forms consortium to fund exome sequencing
12 January 2018   Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB